LBRX · NASDAQ · WEEK ENDED 24 JUL 2026

Weekly Investor Report

LB Pharmaceuticals Inc Common Stock · Healthcare · Biotechnology

LATEST CLOSE

35.01 USD

11.5% latest week

Weekly setup

Constructive, but selective

The weekly trend is active. Price is 29.6% above the Trend Line and sits at 93.2% of its 52-week range. The latest completed week returned 11.5%, after a 9.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 49/100 conviction, while the latest news-sentiment score is 63/100. Near-term considerations: price is close to its 52-week high; earnings are due in 12d.

Technical setup score 65/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

35.01 USD

24 Jul 2026

1W RETURN

11.5%

latest completed week

4W RETURN

9.7%

short-term follow-through

12W RETURN

11.4%

quarterly tape

TREND BREADTH

37.0%

17 of 46 weeks active

VOLUME RATIO

1.8x

vs 13-week average

What is working

- The trend backdrop is active with a 17-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.

What could go wrong

- 13 reversal markers appear in the recent smart-money tape.

What to watch next

- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

11.5%

Latest completed week; four-week move 9.7%.

INDICATOR STACK

65/78

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

OPTIONS PRESSURE

Volatility

49/100 conviction; expected move 17.7%.

NEWS SENTIMENT

63/100

54 relevant articles in the latest sentiment read.

EVENT RISK

12d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is active. Price is 29.6% above the Trend Line and sits at 93.2% of its 52-week range. The latest completed week returned 11.5%, after a 9.7% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range



13.36 USD
36.60 USD

Latest close sits at 93.2% of the 52-week range.

RANGE LOCATION

93.2%

Shows where the latest close sits between the 52-week low and high.

TREND DISTANCE

29.6%

Price premium or discount versus the weekly Trend Line.

FAIR-VALUE GAP

49.0%

Premium demand or model discount versus Sharemaestro Fair Value.

HIGH-WATER GAP

-4.3%

Distance from the latest 52-week high.

02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 1.8x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



PARTICIPATION	BASELINE	ONE-YEAR BASE	LATEST WEEKLY VOLUME
1.8x	1.2M	1.3M	2.1M
Latest volume versus the 13-week average.	13-week average volume.	52-week average volume.	Most recent completed week.

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.

Activity pressure path



Latest 0.81 · 12-week average 0.75

12-week confirmation

Signal	Read	Meaning
Trend active	12/12	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	11/12	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	0/12	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.81	Current proprietary activity-pressure read.
Buy signals	0	Accumulation signal count in the latest 12 weeks.
Reversal markers	13	13 reversal markers

No recent accumulation markers. 13 reversal markers.

03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is 9.7% over four weeks, 11.4% over 12 weeks, and - over one year. The current trend has remained active for 17 consecutive weeks.

Performance by holding period

1W	11.5%
4W	9.7%
12W	11.4%
26W	46.4%
52W	-

ACTIVE TREND STREAK
17 weeks
Consecutive active weeks.

ACTIVE WEEKS
17
Latest 52 weeks.

TREND BREADTH
37.0%
Share of active weeks.

Activity pressure vs relative leadership

Blue: activity pressure · Green: relative leadership

PRESSURE
0.45
Latest activity-pressure read.

PRESSURE CHANGE
246.6%
Four-week change in activity pressure.

LEADERSHIP
-
Latest relative-leadership reading.

RS CHANGE
-
Four-week change in relative leadership.

Technical setup scorecard

Trend	65
Momentum	83
Activity Pressure	78
Relative Leadership	50
Next-Week Expectancy	50
Volume	75
Smart Money	49
Risk Control	70

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

FACTOR WEEK	STATEMENTS THROUGH	FIELD COVERAGE	MODEL CONFIDENCE
26 Jul 2026	31 Dec 2025	61%	58%
Latest published factor snapshot.	Financial reporting period used.	Available factor fields.	Snapshot confidence.

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength	79/100
Value	64/100
Quality	63/100
Momentum	64/100
Growth	64/100

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E Price divided by trailing earnings.	-
PRICE / SALES Market value relative to trailing revenue.	-
EV / EBITDA Enterprise value relative to operating cash earnings.	-
FREE-CASH-FLOW YIELD Free cash flow as a share of enterprise value.	-7.3%

Business quality

Margins and the return generated on invested capital.

GROSS MARGIN Gross profit retained from each unit of revenue.	-
OPERATING MARGIN Operating profit retained from revenue.	-
FREE-CASH-FLOW MARGIN Free cash flow generated from revenue.	-
RETURN ON INVESTED CAPITAL Operating return generated on invested capital.	-48.0%

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength

Recent business growth and accounting strength.

REVENUE GROWTH Latest one-year revenue growth.	-
EPS GROWTH Latest one-year earnings-per-share growth.	-
FREE-CASH-FLOW GROWTH Latest one-year free-cash-flow growth.	-
PIOTROSKI F-SCORE Nine-point accounting-strength checklist.	2/9

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

DIVIDEND YIELD Cash dividends relative to market value.	-
BUYBACK YIELD Net share repurchases relative to market value.	-42.6%
SHAREHOLDER YIELD Dividend yield plus net buyback yield.	-42.6%
NET DEBT / EBITDA Balance-sheet debt relative to operating cash earnings.	8.1x

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Volatility

LBRX shows volatility options pressure with a 49/100 conviction score, put-call volume ratio of 3.44, expected move of 17.7%, and Sharemaestro trend signal active.

CONVICTION

49/100

Options signal conviction.

EXPECTED MOVE

17.7%

Nearest-chain pricing.

PUT/CALL VOLUME

3.44

Contract volume balance.

Pressure	-67
Speculation	29
Volatility	96
Trend agreement	20

Insider activity

-

No recent insider transactions are stored.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

News sentiment

63/100

Weighted news tone is positive across 54 relevant articles.

30 positive · 23 neutral · 1 negative

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal

06 · CATALYSTS AND RISK

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS

12d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.

OPTIONS EXPECTED MOVE

17.7%

Nearest-chain priced movement where available.

52-WEEK DRAWDOWN

-4.3%

Distance below the 52-week high.

13-WEEK VOLATILITY

5.0%

Standard deviation of weekly returns.

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER

15 of 26

11 weeks finished lower.

BEST WEEK

+25.4%

Week of 17 Apr.

WORST WEEK

-10.3%

Week of 30 Jan.

LATEST WEEK

+11.5%

Week of 24 Jul.

Shape of recent returns

Strong gains	8
Modest gains	7
Flat weeks	-
Modest losses	5
Sharp losses	6

RECENT VOL

5.0%

13-week weekly-return volatility.

BASE VOL

7.1%

52-week weekly-return volatility.

UP/DOWN SPLIT

26/19

Count of positive and negative weeks in the 52-week window.

AVERAGE SKEW

6.2% / -4.0%

Average positive week versus average negative week.

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
- / 100	1.3%	51.0%
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Biotechnology

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
- / 100	0.5%	67.0%
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
CRNX	NASDAQ	-0.2%	128.1%	Active
ABVX	NASDAQ	-8.0%	28.9%	Active
BBIO	NASDAQ	3.2%	19.6%	Active
ERAS	NASDAQ	-0.3%	19.4%	Active
IOVA	NASDAQ	-0.2%	17.4%	Active

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	62/100	Trend, activity pressure, participation, and risk combine to a 62/100 tape read.	
Indicator analysis	59/100	Latest 12-week confirmation: trend 12/12, activity pressure 11/12, relative leadership 0/12.	Activity pressure 0.81; 13 reversal markers
Factors	67/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 95; Small Cap Core rank 45
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	40/100	LBRX shows volatility options pressure with a 49/100 conviction score, put-call volume ratio of 3.44, expected move of 17.7%, and Sharemaestro trend signal active.	Volatility · Volatility expansion watch · Expected move 17.7%
Sentiment	63/100	Weighted news tone is positive across 54 relevant articles.	LB Pharmaceuticals Inc $LBRX is Spruce Street Capital LP's 3rd Largest Position
Insiders	50/100	No recent insider transaction evidence is stored.	Not currently available.
Earnings	12d	Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH

11.5%

Latest completed week; four-week move 9.7%.

INDICATOR STACK

65/78

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

OPTIONS PRESSURE

Volatility

49/100 conviction; expected move 17.7%.

NEWS SENTIMENT

63/100

54 relevant articles in the latest sentiment read.

EVENT RISK

12d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	35.01 USD	11.5%	27.01 USD	23.50 USD	0.45	-	2.1M	On
17 Jul 2026	31.41 USD	-4.7%	26.56 USD	23.25 USD	0.47	-	791.4K	On
10 Jul 2026	32.95 USD	-1.4%	26.22 USD	23.06 USD	0.49	-	1.4M	On
03 Jul 2026	33.43 USD	4.7%	25.75 USD	22.83 USD	0.32	-	1.3M	On
26 Jun 2026	31.92 USD	6.4%	25.29 USD	22.58 USD	0.13	-	3.1M	On
19 Jun 2026	30.00 USD	5.6%	24.82 USD	22.35 USD	-0.03	-	1.2M	On
12 Jun 2026	28.42 USD	-0.4%	24.33 USD	22.16 USD	0.05	-	935.0K	On
05 Jun 2026	28.53 USD	2.0%	23.88 USD	22.00 USD	0.31	-	797.3K	On
29 May 2026	27.97 USD	-0.5%	23.44 USD	21.83 USD	0.66	-	796.6K	On
22 May 2026	28.12 USD	-5.2%	23.05 USD	21.66 USD	0.98	-	878.6K	On
15 May 2026	29.66 USD	-7.2%	22.64 USD	21.48 USD	1.23	-	680.3K	On
08 May 2026	31.97 USD	1.7%	22.17 USD	21.25 USD	1.33	-	623.2K	On
01 May 2026	31.43 USD	2.3%	21.62 USD	20.94 USD	1.07	-	792.9K	On
24 Apr 2026	30.73 USD	0.7%	21.08 USD	20.62 USD	0.89	-	1.2M	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Open the live report · Open the interactive chart · Full disclaimer